What question did this study set out to answer?

This study aims to evaluate the efficacy of ABBV-706 in various pediatric cancers that express the SEZ6 protein.

Efficacy of ABBV-706: A SEZ6-Targeted Topoisomerase 1 Inhibitor ADC in Pediatric Cancers

View Full Paper

Ask AI

Bookmark

Authors

A preclinical trial demonstrates ABBV-706's anti-tumor activity in pediatric cancers, suggesting potential clinical applications.

This study aims to evaluate the efficacy of ABBV-706 in various pediatric cancers that express the SEZ6 protein.
Conducted in vivo studies using pediatric xenograft models with SEZ6 expression.
Administered ABBV-706 or isotype control ADC via IP injection in two doses.
Assessed efficacy using median event-free survival and objective response measure.
ABBV-706 showed significant efficacy in non-CNS cancer models with SEZ6 expression.
At DL1, 8 of 11 models demonstrated positive responses (PR, CR, MCR).
At DL2, 9 of 11 models exhibited similar positive outcomes.
In one of two MB models, a survival advantage was noted.

Stewart et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

A preclinical trial demonstrates ABBV-706's anti-tumor activity in pediatric cancers, suggesting potential clinical applications.

This study aims to evaluate the efficacy of ABBV-706 in various pediatric cancers that express the SEZ6 protein.
Conducted in vivo studies using pediatric xenograft models with SEZ6 expression.
Administered ABBV-706 or isotype control ADC via IP injection in two doses.
Assessed efficacy using median event-free survival and objective response measure.
ABBV-706 showed significant efficacy in non-CNS cancer models with SEZ6 expression.
At DL1, 8 of 11 models demonstrated positive responses (PR, CR, MCR).
At DL2, 9 of 11 models exhibited similar positive outcomes.
In one of two MB models, a survival advantage was noted.

Stewart et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark